CLINICAL_TRIALS
trial_result
· 2011-03-28
Clinical Trial Update: Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients [Phase 3]
Summary
A Phase 3 trial of Circadin 2 mg evaluated its efficacy and safety in adults with primary insomnia. Results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Neurim Pharmaceuticals Ltd. | Conditions: Primary Insomnia | Phase 3 | Status: COMPLETED | Results posted: 2011-03-28